Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1585-1587

  Goldman, Mitchell ^a   Cloud, Gretchen A ^b   Smedema, Melinda ^a   Lemonte, Ann ^a   Connolly, Patricia ^a   Mckinsey, David S ^c   Kauffman, Carol A ^d   Moskovitz, Bruce ^e   Wheat, L Joseph ^a,f,h   Flanigan, C ⁱ   Gutsch, H ⁱ   Weissinger, B ⁱ   Baruch, A ⁱ   Dine, A ⁱ   Smith, D ⁱ   Lee, B ⁱ   Nixon, H ⁱ   Bamberger, D ^g   Simpson, D ^g   Black, J ⁱ   Norris, S ⁱ   Slama, T ⁱ   Ryan, S ⁱ   Richardson, J ⁱ   McKinsey, J ⁱ   Lancaster, D ⁱ   Ray, D ⁱ   Threlkeld, M ⁱ   more..

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Infectious Disease Associates of Kansas City   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; HUMANS; ITRACONAZOLE; TIME FACTORS;

EID: 0034120555     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1585-1587.2000     Document Type: Article

References (9)

1. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
2. McKinsey, D. S., L. J. Wheat, G. A. Cloud, M. Pierce, J. R. Black, D. M. Bamberger, M. Goldman, C. J. Thomas, H. M. Gutsch, et al. 1999. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin. Infect. Dis. 28:1049-1056.
3. Phillips, P., J. Zemcov, W. Mahmood, J. S. G. Montaner, K. Craib, and A. M. Clarke. 1996. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10:1369-1376.
4. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, S. G. Hilsenbeck, and T. F. Patterson. 1998. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am. J. Med. 105:7-11.
5. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb. 1995. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
6. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
7. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med, 97:339-346.
8. Snedecor, G. W., and W. G. Cochran. 1980. Statistical methods. Iowa State University Press, Ames.
9. Waitz, J. A., M. S. Bartlett, M. A. Ghannoum, A. Espinel-Ingroff, M. V. Lancaster, F. C. Odds, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, T. J. Walsh, and J. N. Galgiani. 1997. Reference method of broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A, p. 1-29. National Committee for Clinical Laboratory Standards, Wayne, Pa.